Among critically ill patients, many die, and many of the survivors and their family members struggle for years with reduced quality of life. Critically ill patients are treated in intensive care units (ICUs). Here, they receive life support, e.g., mechanical ventilation and advanced support of the circulation (heart and blood vessels) and kidneys. In addition, ICU patients receive many other treatments. It is, however, uncertain if all the treatments provide value for the patients. The desirable effects of many treatments are uncertain, and some may be wasteful or even harmful.
Clinical trials are necessary to validly assess the desirable and undesirable effects of different treatments. However, conventional clinical trials have limitations:
* They typically only assess a single question related to a single comparison of treatments at a time.
* They are often not very flexible, including with regards to the number of participants needed, and this increases the risk that a trial will end up as inconclusive.
* There is no or limited re-use or sharing of infrastructure across trials, leading to duplicate work and resource use.
* Trial participants do usually not benefit from the obtained knowledge before the trial concludes.
* Involvement of patients, family members, and other stakeholders is typically limited, which may decrease the relevance of the questions addressed.
With the Intensive Care Platform Trial (INCEPT), we aim to tackle these challenges by establishing a flexible platform trial that continuously learns from the obtained results. The platform trial may run forever with simultaneous and continuous assessment of many treatments. INCEPT will continuously learn from the accrued data and use these to improve the treatment of both participating and future patients. With INCEPT, we are also building a framework for thorough and extensive involvement of key stakeholders, including patients and family members. INCEPT will improve the way clinical trials are done and increase the probabilities that treatments are improved. This will:
* Directly improve outcomes for ICU patients.
* Relieve a strained healthcare system by discarding inefficient or harmful treatments.
* Ensure that new treatments are beneficial or cost-effective before implementation.
* Lower the costs and burdens of assessing more treatments in the critically ill.
Phase:
PHASE4
Details
Lead Sponsor:
Anders Perner
Collaborators:
Aalborg University Hospital Aarhus University Hospital Bispebjerg Hospital Collaboration of Research in Intensive Care Copenhagen University Hospital, Hvidovre Danish Intensive Care Database Gdstrup Hospital Herlev Hospital Hillerod Hospital, Denmark Karolinska Institutet Kolding Sygehus North Denmark Region Odense University Hospital Oslo University Hospital Randers Regional Hospital Region Capital Denmark Region Zealand Rigshospitalet, Denmark Section of Biostatistics University of Copenhagen, Copenhagen Slagelse Hospital Steno Diabetes Center Copenhagen Tampere University The National University Hospital of Iceland University Hospital, Basel, Switzerland University Medical Center Groningen Viborg Regional Hospital Zealand University Hospital